EE03086B1 - N4-(asendatud-oksükarbonüül)-5'-desoksü-5-fluorotsütidiinid, nende saamise meetod ja neid sisaldavad ravimpreparaadid - Google Patents

N4-(asendatud-oksükarbonüül)-5'-desoksü-5-fluorotsütidiinid, nende saamise meetod ja neid sisaldavad ravimpreparaadid

Info

Publication number: EE03086B1
Authority: EE; Estonia
Prior art keywords: radical; formula; deoxy; fluorocytidines; oxycarbonyl
Prior art date: 1992-12-18

Application number

EE9400154A

Other languages

English (en)

Estonian (et)

Inventor

Arasaki Motohiro

Ishitsuka Hideo

Kuruma Isami

Miwa Masanori

Murasaki Chikako

Shimma Nobuo

Umeda Isao

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-18

Filing date

1994-11-18

Publication date

1998-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03086(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-11-18 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

1998-04-15 Publication of EE03086B1 publication Critical patent/EE03086B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicinal Preparation (AREA)

EE9400154A 1992-12-18 1994-11-18 N4-(asendatud-oksükarbonüül)-5'-desoksü-5-fluorotsütidiinid, nende saamise meetod ja neid sisaldavad ravimpreparaadid EE03086B1 (et)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP92121538		1992-12-18

Publications (1)

Publication Number	Publication Date
EE03086B1 true EE03086B1 (et)	1998-04-15

Family

ID=8210304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9400154A EE03086B1 (et)	1992-12-18	1994-11-18	N4-(asendatud-oksükarbonüül)-5'-desoksü-5-fluorotsütidiinid, nende saamise meetod ja neid sisaldavad ravimpreparaadid

Country Status (40)

Country	Link
US (1)	US5472949A (es)
EP (1)	EP0602454B1 (es)
JP (1)	JP2501297B2 (es)
KR (1)	KR100347218B1 (es)
CN (1)	CN1035617C (es)
AT (1)	ATE137244T1 (es)
AU (1)	AU671491B2 (es)
BG (1)	BG61485B1 (es)
BR (1)	BR9305089A (es)
CA (1)	CA2103324C (es)
CZ (1)	CZ284788B6 (es)
DE (1)	DE69302360T2 (es)
DK (1)	DK0602454T3 (es)
EE (1)	EE03086B1 (es)
ES (1)	ES2086856T3 (es)
FI (1)	FI112365B (es)
GE (1)	GEP20074251B (es)
GR (1)	GR3020286T3 (es)
HR (1)	HRP931430B1 (es)
HU (2)	HU218291B (es)
IL (1)	IL108000A0 (es)
IS (1)	IS4108A (es)
LT (1)	LT3115B (es)
LV (1)	LV10625B (es)
MY (1)	MY109282A (es)
NO (1)	NO300066B1 (es)
NZ (1)	NZ250414A (es)
PH (1)	PH30168A (es)
PL (1)	PL174100B1 (es)
RO (1)	RO112619B1 (es)
RU (2)	RU2493162C1 (es)
SA (1)	SA93140409B1 (es)
SI (1)	SI9300648B (es)
SK (1)	SK281403B6 (es)
SV (1)	SV1993000080A (es)
TW (1)	TW372239B (es)
UA (1)	UA39158C2 (es)
UY (1)	UY23697A1 (es)
YU (1)	YU49411B (es)
ZA (1)	ZA939293B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5476932A (en) *	1994-08-26	1995-12-19	Hoffmann-La Roche Inc.	Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) *	1997-06-02	1999-03-29	Hoffmann La Roche	5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) *	1997-06-02	2009-08-26	F. Hoffmann-La Roche Ag	5'-Deoxy-cytidine derivatives
US6005098A (en) *	1998-02-06	1999-12-21	Hoffmann-La Roche Inc.	5'deoxycytidine derivatives
DK1115391T3 (da) *	1998-09-25	2003-02-10	Warner Lambert Co	Kemoterapi af cancer med acetyldinalin i kombination med gemcitabin, capecitabin eller cisplatin
US20070122481A1 (en) *	1998-11-02	2007-05-31	Elan Corporation Plc	Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP2003523980A (ja) *	2000-02-28	2003-08-12	アベンテイス・フアルマ・ソシエテ・アノニム	カンプトテシンおよびピリミジン誘導体を含んでなる癌の処置のための組成物
WO2001076581A1 (en) *	2000-04-11	2001-10-18	Sayuri Yamada	Curcumin compositions
KR100631754B1 (ko) *	2000-08-09	2006-10-09	주식회사 코오롱	Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR100730768B1 (ko) *	2000-08-09	2007-06-21	코오롱생명과학 주식회사	5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
GB0113374D0 (en) *	2001-06-04	2001-07-25	Jerram Clare	Washing line umbrella
IL162595A0 (en) *	2002-01-14	2005-11-20	Novartis Ag	Combinations comprising epothilones and antimetabolites
CA2477088A1 (en)	2002-02-22	2003-10-02	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
CA2506085A1 (en) *	2002-11-15	2004-06-03	Ronald Lynn Merriman	Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
AU2003233586A1 (en) *	2003-05-20	2005-01-21	Aronex Pharmaceuticals, Inc.	Combination chemotherapy comprising capecitabine and a liposomal platinum complex
DK1689404T3 (da) *	2003-11-13	2009-01-26	Pharma Mar Sau	Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
ATE402185T1 (de) *	2003-12-22	2008-08-15	Hoffmann La Roche	Verfahren für fluorcytidinderivate
KR101313702B1 (ko)	2005-02-03	2013-10-04	와이어쓰	제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1868608A2 (en) *	2005-04-01	2007-12-26	F. Hoffmann-Roche AG	Method for administration of capecitabine
RU2447889C2 (ru)	2005-07-18	2012-04-20	Бипар Сайенсиз, Инк.	Способ лечения рака (варианты)
US20080292729A1 (en)	2005-07-21	2008-11-27	Nuvo Research Inc.	Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
TW200803892A (en)	2005-11-04	2008-01-16	Wyeth Corp	Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
EP2343298B9 (en)	2005-12-13	2020-05-06	Incyte Holdings Corporation	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20100160442A1 (en) *	2006-07-18	2010-06-24	Ossovskaya Valeria S	Formulations for cancer treatment
US20080085310A1 (en) *	2006-10-06	2008-04-10	Maria Oksana Bachynsky	Capecitabine rapidly disintegrating tablets
CN100425617C (zh) *	2006-10-31	2008-10-15	浙江海正药业股份有限公司	一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it)	2007-03-05	2008-09-06	Innovate Biotechnology Srl	2',3'-di-o-acil-5-fluoronucleosidi
EP2137201A2 (en) *	2007-04-20	2009-12-30	Dr. Reddy's Laboratories Ltd.	Process for preparing capecitabine
WO2008145403A1 (en) *	2007-06-01	2008-12-04	Synthon B.V.	Processes related to making capecitabine
RS53245B2 (sr)	2007-06-13	2022-10-31	Incyte Holdings Corp	Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
US7842675B2 (en) *	2007-09-15	2010-11-30	Protia, Llc	Deuterium-enriched capecitabine
WO2009042064A2 (en) *	2007-09-21	2009-04-02	Nektar Therapeutics Al, Corporation	Oligomer-nucleoside phosphate conjugates
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) *	2007-11-19	2011-02-09	한미홀딩스 주식회사	카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es)	2007-12-06	2009-03-18	Richmond Sa Com Ind Y Financie	Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009088989A1 (en) *	2008-01-03	2009-07-16	Plus Chemicals, S.A.	Process for the preparation of capecitabine
US20090311335A1 (en) *	2008-06-12	2009-12-17	Scott Jenkins	Combination of a triptan and an nsaid
DK2310011T3 (da)	2008-06-17	2013-10-14	Wyeth Llc	Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
KR101434009B1 (ko) *	2008-08-04	2014-08-25	와이어쓰 엘엘씨	4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
WO2010065586A2 (en) *	2008-12-02	2010-06-10	Dr. Reddy's Laboratories Ltd.	Preparation of capecitabine
WO2010063080A1 (en) *	2008-12-05	2010-06-10	Commonwealth Scientific And Industrial Research Organisation	Amphiphile prodrugs
US9211291B2 (en)	2009-04-06	2015-12-15	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
FR2945211A1 (fr)	2009-05-06	2010-11-12	Sanofi Aventis	Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
HRP20192203T1 (hr)	2009-05-22	2020-03-06	Incyte Holdings Corporation	3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
WO2011010967A1 (en) *	2009-07-23	2011-01-27	Scinopharm Taiwan Ltd.	Process for producing flurocytidine derivatives
WO2011067588A1 (en)	2009-12-04	2011-06-09	Generics [Uk] Limited	Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) *	2010-02-24	2011-09-01	Generics [Uk] Limited	One step process for the preparation of capecitabine
SI3354652T1 (sl)	2010-03-10	2020-08-31	Incyte Holdings Corporation	Derivati piperidin-4-il azetidina kot inhibitorji JAK1
DK2835053T3 (en)	2010-03-12	2016-08-15	Genzyme Corp	Combination therapy to treat breast cancer
MY161078A (en)	2010-05-21	2017-04-14	Incyte Holdings Corp	Topical formulation for a jak inhibitor
CN102260309B (zh) *	2010-05-24	2014-10-22	重庆福安药业(集团)股份有限公司	一种高纯度卡培他滨的制备方法
JP5917545B2 (ja)	2010-11-19	2016-05-18	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
CN102558262A (zh) *	2010-12-23	2012-07-11	天津泰普药品科技发展有限公司	一种高纯度卡培他滨的制备方法
PE20140832A1 (es)	2011-06-20	2014-07-14	Incyte Corp	Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN102266303A (zh) *	2011-07-07	2011-12-07	程雪翔	一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) *	2011-12-09	2014-04-02	海南锦瑞制药股份有限公司	一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) *	2012-01-13	2016-12-01	Pharmaessentia Corp	Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
TWI702057B (zh)	2012-11-15	2020-08-21	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
ES2900492T3 (es)	2013-03-06	2022-03-17	Incyte Holdings Corp	Procesos y productos intermedios para elaborar un inhibidor de JAK
RS60469B1 (sr)	2013-08-07	2020-07-31	Incyte Corp	Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
WO2015026818A1 (en) *	2013-08-20	2015-02-26	Incyte Corporation	Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en)	2013-12-13	2015-06-17	Plasmia Biotech, S.L.	Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) *	2013-12-18	2014-07-02	吉林修正药业新药开发有限公司	一种卡培他滨异构体的制备方法
WO2015191563A1 (en)	2014-06-09	2015-12-17	Lipomedix Pharmaceuticals Ltd.	Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN104530164A (zh) *	2014-12-31	2015-04-22	辰欣药业股份有限公司	一种卡培他滨的合成工艺
KR20160117060A (ko)	2015-03-31	2016-10-10	이승주	유아용 탁자
CN105646625B (zh) *	2015-12-29	2019-06-11	江苏吴中医药集团有限公司	一种卡培他滨的制备方法
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
EP4046989A1 (en)	2017-01-09	2022-08-24	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) *	2017-02-20	2017-07-21	Anadolu Ueniversitesi	Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en)	2017-10-03	2019-10-08	Nucorion Pharmaceuticals, Inc.	5-fluorouridine monophosphate cyclic triester compounds
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
US11407723B2 (en)	2018-01-09	2022-08-09	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
CN117402189A (zh)	2018-01-10	2024-01-16	广东集宝医药技术有限公司	氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
US11427550B2 (en)	2018-01-19	2022-08-30	Nucorion Pharmaceuticals, Inc.	5-fluorouracil compounds
CN111801339B (zh) *	2018-01-19	2025-06-24	纽科利制药公司	5-氟尿嘧啶化合物
PT3746429T (pt)	2018-01-30	2022-06-20	Incyte Corp	Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
EP4424328A3 (en)	2018-03-30	2024-12-04	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
US12171746B2 (en)	2019-01-11	2024-12-24	Lipomedix Pharmaceuticals Ltd.	Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
US12110311B2 (en)	2019-07-17	2024-10-08	Nucorion Pharmaceuticals, Inc.	Cyclic deoxyribonucleotide compounds
WO2021216427A1 (en)	2020-04-21	2021-10-28	Ligand Pharmaceuticals, Inc.	Nucleotide prodrug compounds
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
EP4204428A4 (en)	2020-08-31	2025-03-26	Emory University	5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF AND USES THEREOF
WO2023177894A1 (en)	2022-03-18	2023-09-21	Ideaya Biosciences, Inc.	Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (en)	2022-12-05	2025-08-27	a Fine House S.A.	Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1135258A (en) *	1979-06-15	1982-11-09	Richard D'souza	Process for the preparation of 5'deoxy-5-fluorouridine
DE3587500T2 (de) *	1984-12-04	1993-12-16	Lilly Co Eli	Tumorbehandlung bei Säugetieren.
CA1327358C (en) *	1987-11-17	1994-03-01	Morio Fujiu	Fluoro cytidine derivatives

1993
- 1993-11-12 AU AU50690/93A patent/AU671491B2/en not_active Expired
- 1993-11-15 TW TW082109533A patent/TW372239B/zh not_active IP Right Cessation
- 1993-11-17 CA CA002103324A patent/CA2103324C/en not_active Expired - Lifetime
- 1993-11-23 HR HR92121538.0A patent/HRP931430B1/xx not_active IP Right Cessation
- 1993-12-01 AT AT93119349T patent/ATE137244T1/de active
- 1993-12-01 DK DK93119349.4T patent/DK0602454T3/da active
- 1993-12-01 EP EP93119349A patent/EP0602454B1/en not_active Expired - Lifetime
- 1993-12-01 DE DE69302360T patent/DE69302360T2/de not_active Expired - Lifetime
- 1993-12-01 ES ES93119349T patent/ES2086856T3/es not_active Expired - Lifetime
- 1993-12-07 SA SA93140409A patent/SA93140409B1/ar unknown
- 1993-12-10 ZA ZA939293A patent/ZA939293B/xx unknown
- 1993-12-10 HU HU9303525A patent/HU218291B/hu active Protection Beyond IP Right Term
- 1993-12-10 NZ NZ250414A patent/NZ250414A/en not_active IP Right Cessation
- 1993-12-10 SI SI9300648A patent/SI9300648B/sl unknown
- 1993-12-13 CZ CZ932731A patent/CZ284788B6/cs not_active IP Right Cessation
- 1993-12-13 IL IL10800093A patent/IL108000A0/xx not_active IP Right Cessation
- 1993-12-14 FI FI935616A patent/FI112365B/fi not_active IP Right Cessation
- 1993-12-14 US US08/167,392 patent/US5472949A/en not_active Expired - Lifetime
- 1993-12-15 RO RO93-01706A patent/RO112619B1/ro unknown
- 1993-12-15 PH PH47455A patent/PH30168A/en unknown
- 1993-12-15 YU YU77993A patent/YU49411B/sh unknown
- 1993-12-16 BR BR9305089A patent/BR9305089A/pt not_active Application Discontinuation
- 1993-12-16 RU RU2012134029/04A patent/RU2493162C1/ru not_active IP Right Cessation
- 1993-12-16 KR KR1019930027962A patent/KR100347218B1/ko not_active Expired - Lifetime
- 1993-12-16 BG BG98304A patent/BG61485B1/bg unknown
- 1993-12-16 MY MYPI93002726A patent/MY109282A/en unknown
- 1993-12-16 RU RU93056196/04A patent/RU2458932C2/ru active Protection Beyond IP Right Term
- 1993-12-16 JP JP5342812A patent/JP2501297B2/ja not_active Expired - Fee Related
- 1993-12-17 LT LTIP1627A patent/LT3115B/lt not_active IP Right Cessation
- 1993-12-17 IS IS4108A patent/IS4108A/is unknown
- 1993-12-17 CN CN93112838A patent/CN1035617C/zh not_active Expired - Lifetime
- 1993-12-17 LV LVP-93-1347A patent/LV10625B/en unknown
- 1993-12-17 NO NO934671A patent/NO300066B1/no not_active IP Right Cessation
- 1993-12-17 SV SV1993000080A patent/SV1993000080A/es not_active Application Discontinuation
- 1993-12-17 UA UA93004687A patent/UA39158C2/uk unknown
- 1993-12-17 PL PL93301541A patent/PL174100B1/pl unknown
- 1993-12-17 SK SK1444-93A patent/SK281403B6/sk not_active IP Right Cessation
- 1993-12-17 UY UY23697A patent/UY23697A1/es not_active IP Right Cessation
1994
- 1994-11-18 EE EE9400154A patent/EE03086B1/xx not_active IP Right Cessation
1995
- 1995-06-19 HU HU95P/P00255P patent/HU211965A9/hu unknown
1996
- 1996-06-19 GR GR960401668T patent/GR3020286T3/el unknown
2006
- 2006-07-17 GE GEAP20069525A patent/GEP20074251B/en unknown

Also Published As

Publication number	Publication date
MY109282A (en)	1996-12-31
BR9305089A (pt)	1994-07-05
GEP20074251B (en)	2007-12-10
SK144493A3 (en)	1994-10-05
FI935616A0 (fi)	1993-12-14
SI9300648A (en)	1994-09-30
LV10625A (lv)	1995-04-20
DE69302360T2 (de)	1996-10-31
DK0602454T3 (da)	1996-07-29
PL301541A1 (en)	1994-06-27
ES2086856T3 (es)	1996-07-01
NO300066B1 (no)	1997-04-01
CN1094056A (zh)	1994-10-26
FI112365B (fi)	2003-11-28
IL108000A0 (en)	1994-04-12
YU77993A (sh)	1996-10-18
EP0602454A1 (en)	1994-06-22
HK1005875A1 (en)	1999-01-29
RU2493162C1 (ru)	2013-09-20
SA93140409B1 (ar)	2004-07-24
SK281403B6 (sk)	2001-03-12
UA39158C2 (uk)	2001-06-15
PH30168A (en)	1997-01-21
JP2501297B2 (ja)	1996-05-29
HRP931430B1 (en)	1999-08-31
SI9300648B (sl)	2000-06-30
CZ273193A3 (en)	1994-07-13
TW372239B (en)	1999-10-21
ATE137244T1 (de)	1996-05-15
NZ250414A (en)	1995-12-21
AU5069093A (en)	1994-06-30
YU49411B (sh)	2006-01-16
CA2103324A1 (en)	1994-06-19
LTIP1627A (en)	1994-07-15
KR940014428A (ko)	1994-07-18
CA2103324C (en)	1997-12-23
NO934671L (no)	1994-06-20
LT3115B (en)	1994-12-27
CZ284788B6 (cs)	1999-03-17
NO934671D0 (no)	1993-12-17
LV10625B (en)	1996-04-20
BG98304A (bg)	1994-01-03
UY23697A1 (es)	1994-06-08
SV1993000080A (es)	1996-01-26
CN1035617C (zh)	1997-08-13
AU671491B2 (en)	1996-08-29
HUT65757A (en)	1994-07-28
JPH06211891A (ja)	1994-08-02
RU2458932C2 (ru)	2012-08-20
RU2135511C1 (ru)	1999-08-27
HU211965A9 (en)	1996-01-29
GR3020286T3 (en)	1996-09-30
RO112619B1 (ro)	1997-11-28
US5472949A (en)	1995-12-05
DE69302360D1 (de)	1996-05-30
FI935616L (fi)	1994-06-19
KR100347218B1 (ko)	2003-01-24
HU9303525D0 (en)	1994-04-28
HRP931430A2 (en)	1998-06-30
PL174100B1 (pl)	1998-06-30
EP0602454B1 (en)	1996-04-24
BG61485B1 (bg)	1997-09-30
IS4108A (is)	1994-06-19
HU218291B (en)	2000-07-28
ZA939293B (en)	1994-06-18

Publication	Publication Date	Title
EE03086B1 (et)	1998-04-15	N4-(asendatud-oksükarbonüül)-5'-desoksü-5-fluorotsütidiinid, nende saamise meetod ja neid sisaldavad ravimpreparaadid
RU93056196A (ru)	1997-03-27	N-карбонилзамещенные 5'-дезокси-5-фторцитидина
NZ231983A (en)	1992-12-23	Substituted 1,3-diazoles and 1,2,4-triazoles; fungicidal compositions, methods for preparation and combating fungal disease
ZA898678B (en)	1990-09-26	Compositions and compounds
HU9401976D0 (en)	1994-09-28	N,n'-substituted imidocarbonimidic diamides, pharmaceutical compositions containing them and use of these compounds aganst infection
FR2702480B1 (fr)	1995-04-28	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
EP0401715A3 (en)	1992-03-04	Aminoketone compounds
GR3003472T3 (en)	1993-02-17	1-benzoyl-2-oxo-5-alkoxy-pyrrolidine derivatives, their preparation, their use and preparations containing them
ATE168995T1 (de)	1998-08-15	N-(mercaptoacyl)aminosäure, ihre herstellung, ihre therapeutische verwendung und sie enthaltende pharmazeutische zusammensetzungen
ES2023760A6 (es)	1992-02-01	Procedimiento para la preparacion de derivados benzotiazinicos.

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2010-02-15	KB4A	Valid patent at the end of a year	Effective date: 20091231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2017-02-15	SPCX	Term of validity of supplementary protection expired	Spc suppl protection certif: 00001 Extension date: 20130610